Mereo BioPharma Group (NASDAQ:MREO) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Mereo BioPharma Group (NASDAQ:MREO – Free Report) in a research report released on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $6.00 price objective on shares of […]

Related Keywords

United Kingdom ,United States , ,Advisors Preferred ,News Ratings For Mereo Biopharma Group Daily ,Mereo Biopharma Group ,Mereo Biopharma Group Price Performance ,Sg Americas Securities ,Needham Company ,Mereo Biopharma Group Company Profile ,Cantor Fitzgerald ,Index Fund Advisors Inc ,Free Report ,Biopharma Group ,State Equity Partners ,Financial Markets ,Index Fund Advisors ,Get Free Report ,Mereo Biopharma Group Daily ,